Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American journal of hematology/oncology

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.25071PMID 29634090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hodgkin lymphoma

  2019cited by this paper
• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

  2018cited by this paper
• Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

  2018cited by this paper
• Cancer statistics, 2018

  2018cited by this paper
• Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

  2017influential reference
• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

  2017cited by this paper
• Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

  2017cited by this paper
• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

  2017cited by this paper
• PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

  2017cited by this paper
• Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

  2017cited by this paper
• Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

  2016cited by this paper
• Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

  2016cited by this paper
• Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

  2016cited by this paper
• PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

  2016cited by this paper
• Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

  2015cited by this paper
• A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).

  2015cited by this paper
• Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

  2013cited by this paper
• Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.

  2013influential reference
• Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

  2013cited by this paper
• German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

  2013cited by this paper
• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

  2012cited by this paper
• Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

  2012cited by this paper
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012cited by this paper
• PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

  2012cited by this paper
• Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

  2012cited by this paper
• Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

  2012cited by this paper
• Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study.

  2012cited by this paper
• Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

  2012cited by this paper
• ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

  2012cited by this paper
• Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

  2011cited by this paper
• Hodgkin's lymphoma--the great teacher.

  2011cited by this paper
• Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.

  2011cited by this paper
• ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

  2011cited by this paper
• ABVD versus BEACOPP for Hodgkin's lymphoma.

  2011cited by this paper
• ABVD versus BEACOPP for Hodgkin's lymphoma.

  2011cited by this paper
• Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

  2010cited by this paper
• Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

  2010cited by this paper
• Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

  2010cited by this paper
• Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

  2009influential reference
• ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

  2009cited by this paper
• Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

  2009cited by this paper
• Targeting PI3K signalling in cancer: opportunities, challenges and limitations

  2009cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

  2008cited by this paper
• Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

  2008influential reference
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007influential reference
• Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

  2007cited by this paper
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

  2006cited by this paper
• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

  2005cited by this paper
• Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results.

  2004cited by this paper
• ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.

  2004cited by this paper
• Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

  2003cited by this paper
• High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

  2003cited by this paper
• Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

  2003cited by this paper
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

  2003cited by this paper
• Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

  2003cited by this paper
• Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  2003cited by this paper
• Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease.

  2003cited by this paper
• Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

  2003cited by this paper
• Hodgkin's disease.

  2002cited by this paper
• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

  2002cited by this paper
• Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.

  2002cited by this paper
• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

  2002cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

  2001cited by this paper
• Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.

  2000cited by this paper
• Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents

  2000cited by this paper
• Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.

  2000cited by this paper
• Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.

  2000cited by this paper
• Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

  2000cited by this paper
• A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE

  2000influential reference
• Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group.

  1999cited by this paper
• Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

  1999cited by this paper
• Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

  1999cited by this paper
• Pseudoautosomal linkage of Hodgkin disease.

  1999influential reference
• ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.

  1999cited by this paper
• Advances in the epidemiology of HIV‐associated non‐Hodgkin's lymphoma and other lymphoid neoplasms

  1999cited by this paper
• The role of positron emission tomography (PET) in the management of lymphoma patients.

  1999cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

  1999cited by this paper
• Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.

  1999cited by this paper
• A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

  1998cited by this paper
• Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome.

  1998cited by this paper
• Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

  1998cited by this paper
• Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.

  1997cited by this paper
• Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry

  1997cited by this paper
• Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

  1997cited by this paper
• BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.

  1997cited by this paper
• Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.

  1997cited by this paper
• Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

  1997cited by this paper
• Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.

  1996cited by this paper
• The epidemiology of Hodgkin's disease.

  1996cited by this paper
• Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells

  1996cited by this paper
• Vinorelbine: a new promising drug in Hodgkin's disease.

  1996cited by this paper
• Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease.

  1995influential reference
• Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.

  1995cited by this paper
• The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.

  1995cited by this paper
• High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.

  1995cited by this paper

• Global, regional, and national patterns of change in the burden of Hodgkin lymphoma from 1990 to 2021: an analysis of the global burden of disease study 2021 and projections to 2035

  2026cites this paper
• Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021

  2025influential citation
• PRIMARY PULMONARY HODGKIN'S LYMPHOMA: A CASE OF DIAGNOSTIC COMPLEXITY AND TREATMENT RESISTANCE

  2025cites this paper
• Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma

  2025cites this paper
• Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers

  2025cites this paper
• The relationship between toll-like receptors 9 gene rs5743836 polymorphism and lymphoma risk: a meta-analysis

  2025cites this paper
• The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients

  2025cites this paper
• What Is Still Unclear or Unresolved in Classic Hodgkin Lymphoma Pathobiology, Diagnosis, and Treatment

  2025cites this paper
• Pentoxifylline Enhances the Effects of Doxorubicin and Bleomycin on Apoptosis, Caspase Activity, and Cell Cycle While Reducing Proliferation and Senescence in Hodgkin’s Disease Cell Line

  2025cites this paper
• Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of Classical Hodgkin Lymphoma.

  2024cites this paper
• Evaluation of primary musculocutaneous Hodgkin’s lymphoma with the aid of 18F FDG PET/CT – a rare entity

  2024cites this paper
• Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• LINFOMA NÃO-HODGKIN DE CÉLULAS DO MANTO

  2024cites this paper
• Getting the right combination to break the epigenetic code

  2024cites this paper
• Hodgkin’s Lymphoma in a 34-Year-Old Patient with Digital Clubbing: A Case Report

  2024cites this paper
• Clinical Profile and Outcome of Adult Classical Hodgkin’s Lymphoma: Real World Single Centre Experience

  2024cites this paper
• Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes

  2024cites this paper
• CRISPR/Cas9 screening: unraveling cancer immunotherapy's 'Rosetta Stone'.

  2024cites this paper
• Ibrutinib Combined with Compound Realgar Natural Indigo Tablets for the Treatment of Relapsed and Refractory Hodgkin Lymphoma: A Case Report and Literature Review

  2024cites this paper
• Primary pulmonary Hodgkin’s lymphoma mimicking granulomatosis with polyangiitis – a case report of diagnostic and therapeutic dilemmas

  2023cites this paper
• Management of limited-stage Hodgkin lymphoma.

  2023cites this paper
• Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System

  2023cites this paper
• Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.

  2023cites this paper
• Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry

  2023cites this paper
• Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

  2023cites this paper
• Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma

  2023cites this paper
• Vanishing Bile Duct Syndrome in a Patient With Recurrent Hodgkin Lymphoma

  2023cites this paper
• Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2.

  2023cites this paper
• The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy

  2023cites this paper
• Calculated Globulin as a potential screening tool for paraproteinemia to aid in the early diagnosis of Multiple Myeloma.

  2023cites this paper
• Composite Biomarker Image for Advanced Visualization in Histopathology

  2023cites this paper
• Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial

  2023cites this paper
• Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

  2023cites this paper
• Advances in the treatment of Hodgkin lymphoma: Current and future approaches

  2023cites this paper
• Immunotherapy for Hodgkin lymphoma: from monoclonal antibodies to chimeric antigen receptor T-cell therapy.

  2023cites this paper
• The prognostıc significance of blood counts in patients with hodgkin lymphoma

  2022cites this paper
• A RETROSPECTIVE ANALYSIS OF EPIDEMIOLOGY AND CLINICAL OUTCOME OF HODGKIN LYMPHOMA PATIENTS IN CLINICAL ONCOLOGY DEPARTMENT IN AIN SHAMS UNIVERSITY HOSPITALS IN EGYPT.

  2022cites this paper
• Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

  2022cites this paper
• Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

  2022cites this paper
• Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse

  2022cites this paper
• Milestones in Hematology and Oncology: From Fatal to Curable Disease

  2022cites this paper
• Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

  2022cites this paper
• Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma

  2022cites this paper
• Cancer treatment and survivorship statistics, 2022

  2022cites this paper
• Long‐term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors

  2022cites this paper
• Risk of Pulmonary Toxicity and Benefits of Bleomycin Containing Regimen in Early-Stage Hodgkin's Lymphoma - A Case Report and Insights from Literature Review

  2022cites this paper
• Consecutive Inhibition of Telomerase and Alternative Lengthening Pathway Promotes Hodgkin’s Lymphoma Cell Death

  2022cites this paper
• The "Hand as Foot" memorizing method in radiation field of Hodgkin lymphoma.

  2022cites this paper
• Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review

  2022cites this paper
• What Lies Behind the Cannonball Pulmonary Metastases: Hodgkin's Lymphoma?

  2022influential citation
• Liposome-Loaded Targeted Theranostic Fluorescent Nano-Probes for Diagnosis and Treatment of Cervix Carcinoma

  2022cites this paper
• First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes

  2022cites this paper
• Cutaneous Involvement in Hodgkin Lymphoma: A Rare Case Report

  2022cites this paper
• Durable remission for four pediatric patients with high‐risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group

  2022cites this paper
• Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes

  2022cites this paper
• First Extensive Analysis of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis

  2022cites this paper
• What can machine vision do for lymphatic histopathology image analysis: a comprehensive review

  2022cites this paper
• Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors

  2022cites this paper
• High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome

  2022cites this paper
• Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma

  2021cites this paper
• Treatment of lymphomas via regulating the Signal transduction pathways by natural therapeutic approaches: A review.

  2021cites this paper
• A Rare Case of Hodgkin Lymphoma of the Maxillary Sinus

  2021cites this paper
• The derived neutrophil-lymphocyte ratio and the neutrophil-lymphocyte ratio are related to poor prognosis in Hodgkin lymphoma patients.

  2021cites this paper
• Immune checkpoint inhibitors in the treatment of cancer.

  2021cites this paper
• Immune checkpoint inhibition in classical hodgkin lymphoma

  2021cites this paper
• Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.

  2021cites this paper
• Immunomodulatory and Anti-Inflammatory Properties of Glucocorticoids

  2021cites this paper
• Pineal gland hypermetabolic involvement without central nervous system symptoms in a pediatric patient with primary nodular sclerosis subtype classical Hodgkin Lymphoma

  2021cites this paper
• Synchronous Occurrence of Hodgkin’s Lymphoma and Lung Cancer

  2021cites this paper
• Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma.

  2021cites this paper
• An Unusual Hodgkin's Lymphoma Journey: Cardiac Tamponade, Primary Refractoriness, Immune Thrombocytopenia, and Post-Traumatic Stress Disorder

  2021cites this paper
• Isolated B-cell lymphopenia and autoimmune hemolytic anemia as a curious combination of findings at the time of advanced Hodgkin lymphoma diagnosis: a pediatric case report.

  2021cites this paper
• Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.

  2021cites this paper
• Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.

  2021cites this paper
• A Systematic Assessment of the Epidemiologic Literature Regarding an Association between Acetaminophen Exposure and Cancer.

  2021cites this paper
• Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma

  2021cites this paper
• A 51-Year-Old Man With a Large Posterior Mediastinal Mass.

  2021cites this paper
• Digital Clubbing and Hodgkin Disease in Children: A Case Report and Review of Literature

  2021cites this paper
• Recurrence-specific supervised graph clustering for subtyping Hodgkin Lymphoma radiomic phenotypes

  2021cites this paper
• Hodgkin Lymphoma: Recent Progress in Overall Management

  2021cites this paper
• Radiomic Features of 18F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes

  2021cites this paper
• Cluster of Differentiation 274 Antigen Immunohistochemical Expression in Tumor and Peri-tumor Cells of Hodgkin and Non-Hodgkin Lymphoma and Clinicopathological Relation (Single-center Study)

  2021cites this paper
• Abstract

  2021cites this paper
• A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope

  2021cites this paper
• Lymphoma, Hematological Neoplasia, and Metastases of the Oral Cavity

  2021cites this paper
• Incidence, Clinic Presentation, and Outcomes of Pneumocystis Pneumonia when Utilizing Polymerase Chain Reaction-Based Diagnosis in Patients with Hodgkin Lymphoma

  2021cites this paper
• Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies

  2020cites this paper
• Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

  2020cites this paper
• Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future

  2020influential citation
• Saudi Lymphoma Group‘s Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic

  2020cites this paper
• Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment

  2020cites this paper
• Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma

  2020cites this paper
• Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome.

  2020cites this paper
• Treatment of very high-risk classical Hodgkin Lymphoma: cases’ selection from real life and critical review of the literature

  2020cites this paper
• ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.

  2020cites this paper
• Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

  2020cites this paper
• Methodological framework for radiomics applications in Hodgkin’s lymphoma

  2020cites this paper
• Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy

  2020cites this paper
• The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review

  2020cites this paper